Use of metabolic glycoengineering and pharmacological inhibitors to assess lipid and protein sialylation on cells

Metabolic glycoengineering (MGE) has been developed to visualize carbohydrates on live cells. The method allows the fluorescent labeling of sialic acid (Sia) sugar residues on neuronal plasma membranes. For instance, the efficiency of glycosylation along neurite membranes has been characterized as c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurochemistry 2023-02, Vol.164 (4), p.481-498
Main Authors: Kranaster, Petra, Blum, Jonathan, Dold, Jeremias E. G. A., Wittmann, Valentin, Leist, Marcel
Format: Article
Language:English
Subjects:
Biomolecules
Carbohydrates
Cell adhesion
Cell adhesion molecules
Cell membranes
confocal imaging
Dopamine receptors
Fluorescence
ganglioside
Glycoproteins
Glycoproteins - metabolism
Glycosylation
Hepatoma
Humans
Labeling
Lipids
Membranes
metabolic glycoengineering
Metabolism
N-Acetylneuraminic Acid - metabolism
Neural cell adhesion molecule
Neural Cell Adhesion Molecules - metabolism
Neural crest
neuron
Neurons
Plasma membranes
Polysialic acid
Proteins
Sensory neurons
sialic acid
Sialic Acids - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic glycoengineering (MGE) has been developed to visualize carbohydrates on live cells. The method allows the fluorescent labeling of sialic acid (Sia) sugar residues on neuronal plasma membranes. For instance, the efficiency of glycosylation along neurite membranes has been characterized as cell health measure in neurotoxicology. Using human dopaminergic neurons as model system, we asked here, whether it was possible to separately label diverse classes of biomolecules and to visualize them selectively on cells. Several approaches suggest that a large proportion of Sia rather incorporated in non‐protein components of cell membranes than into glycoproteins. We made use here of deoxymannojirimycin (dMM), a non‐toxic inhibitor of protein glycosylation, and of N‐butyl‐deoxynojirimycin (NBdNM) a well‐tolerated inhibitor of lipid glycosylation, to develop a method of differential labeling of sialylated membrane lipids (lipid‐Sia) or sialylated N‐glycosylated proteins (protein‐Sia) on live neurons. The time resolution at which Sia modification of lipids/proteins was observable was in the range of few hours. The approach was then extended to several other cell types. Using this technique of target‐specific MGE, we found that in dopaminergic or sensory neurons >60% of Sia is lipid bound, and thus polysialic acid‐neural cell adhesion molecule (PSA‐NCAM) cannot be considered the major sialylated membrane component. Different from neurons, most Sia was bound to protein in HepG2 hepatoma cells or in neural crest cells. Thus, our method allows visualization of cell‐specific sialylation processes for separate classes of membrane constituents. Selective labeling and visualization of diverse groups of glycans on cells is challenging. We developed a modified metabolic glycoengineering approach. It used deoxymannojirimycin, a non‐toxic inhibitor of protein glycosylation, and N‐butyl‐deoxynojirimycin, a well‐tolerated inhibitor of lipid glycosylation, to differentially label sialylated membrane lipids or sialylated N‐glycosylated proteins on live neurons. We found that in dopaminergic or sensory neurons >60% of sialic acid is lipid bound. In contrast to this, most sialic acid was bound to protein in hepatoma cells or in neural crest cells.
ISSN:0022-3042
1471-4159
DOI:10.1111/jnc.15737